Bioinformatics and In Vitro Study Reveal ERα as The Potential Target Gene of Honokiol to Enhance Trastuzumab Sensitivity in HER2+ Trastuzumab-Resistant Breast Cancer Cells
-
Published:2024-08
Issue:
Volume:111
Page:108084
-
ISSN:1476-9271
-
Container-title:Computational Biology and Chemistry
-
language:en
-
Short-container-title:Computational Biology and Chemistry
Author:
Putra I Made Rhamanadana,
Lestari Intan Ayu,
Fatimah Nurul,
Hanif NaufaORCID,
Ujiantari Navista Sri Octa,
Putri Dyaningtyas Dewi Pamungkas,
Hermawan AdamORCID
Funder
Gadjah Mada University
Reference66 articles.
1. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial;André;Lancet Oncol.,2014
2. Acquired resistance to aromatase inhibitors: where we stand!;Augusto;Endocr. Relat. Cancer,2018
3. MDM2 is a potential target gene of Glycyrrhizic acid for circumventing breast cancer resistance to tamoxifen: integrative bioinformatics analysis;Azzahra;Asian Pac. J. Cancer Prev.,2022
4. Honokiol for cancer therapeutics: a traditional medicine that can modulate multiple oncogenic targets;Banik;Pharmacol. Res.,2019
5. Randomized study of Lapatinib alone or in combination with trastuzumab in women With ErbB2-positive, trastuzumab-refractory metastatic breast cancer;Blackwell;J. Clin. Oncol.,2010
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献